ClinicalTrials.gg
RecruitingNCT07037576Updated Jun 25, 2025

Efficacy and Safety of Prepectoral Prosthesis Immediate One-Stage Breast Reconstruction Versus Two-Stage Expander/Prosthesis Reconstruction in Postoperative Adjuvant Radiotherapy Breast Cancer Patients: A Prospective, Single-Center, Cohort Study

An observational study in Breast Cancer Patients, sponsored by Henan Cancer Hospital. Recruiting at 1 site in China. Open to female participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2025-06-25.

Sponsored by Henan Cancer Hospital · Observational

How we know

From the registry’s dates

  • Started May 2025; still recruiting 1 year 6 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
104
Ages
18 Years to 70 Years
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 45 studies in Breast Neoplasms by Henan Cancer Hospital — 29 open to participants now, 32 under way, 3 of them phase 3. Breast Neoplasms · Henan Cancer Hospital.

Started
2025
with 10 others
Observational
5 of 45
4 open now
Primary completion
2027-03
later than 13 of 31 live
Registered
36th of 45
by date

Among the 45 studies in Breast Neoplasms by Henan Cancer Hospital, this one is one of 11 that started in 2025, is one of 5 observational ones, reaches primary completion later than 13 of the 31 other live ones, and was the 36th registered.

Breast Neoplasms

14,855 studies on the registry are indexed under Breast Neoplasms; 3,321 are open to participants now.

Browse Breast Neoplasms studies →

Open to participants now

29 of the 45 studies in Breast Neoplasms by Henan Cancer Hospital are open now, in 1 country. Recruiting first, the newest first:

23 more — sign in →

By country, each count listing its studies:

All 29 open studies →

Where they have run

Who these studies take

Of the 2,403 Breast Neoplasms studies recruiting now, 1,574 (66%) set no upper age limit and 591 (25%) stop at 75 or younger; 103 take children under 18; 215 take healthy volunteers.

This study: 18 Years to 70 Years · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 45 studies in Breast Neoplasms by Henan Cancer Hospital, or all of them as a file.
02

Study summary

Prospective Evaluation of the Efficacy and Safety of Prepectoral Immediate One-Stage Prosthetic Breast Reconstruction Versus Two-Stage Expander/Prosthesis Reconstruction in Postoperative Adjuvant Radiotherapy Breast Cancer Patients

Read the detailed description

This study is a prospective, double-cohort study. It plans to enroll more than 104 patients with cT1-3N0-3M0 breast cancer for immediate prepectoral muscle prosthesis reconstruction or two-step breast reconstruction with expander/prosthesis, and they will receive postoperative radiotherapy. Record the changes of BREAST-Q scores of the patients before and after the operation, as well as information such as postoperative complications and capsular contracture.

The primary endpoint was the BREAST-Q score at 12 months after the operation. The secondary endpoints included the success rate of breast reconstruction, surgical complications, cosmetic effects of the breast evaluated by doctors, the occurrence of capsular contracture, nipple and skin sensation, and tumor safety.

03

Conditions studied

  • Breast Cancer Patients

Browse trials for

Keywords

  • Breast cancer
  • Breast reconstruction surgery
  • Radiotherapy
04

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
Female
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Treatment-naïve women with unilateral primary breast cancer (clinical stage cT1-3N0-3M0) scheduled for immediate prepectoral direct-to-implant reconstruction OR tissue expander/implant two-stage reconstruction, followed by adjuvant radiotherapy.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. women aged 18 to 70;
  2. Newly diagnosed breast cancer patients showing no evidence of distant on clinical examination and diagnostic workup;
  3. radiotherapy is required;
  4. Patients scheduled to undergo nipple-sparing mastectomy (NSM) or skin-sparing mastectomy (SSM) with immediate prepectoral implant-based reconstruction (via open, endoscopic, or robotic approach) require adjuvant radiotherapy AFTER permanent implant placement; OR Patients scheduled for NSM/SSM with two-stage tissue expander/implant reconstruction (with expander placement in either submuscular or prepectoral plane) receive radiotherapy WITH the tissue expander in situ, followed by exchange for permanent implant ≥6 months post-radiotherapy (expander position: submuscular/prepectoral acceptable; surgical approach: open/endoscopic/robotic acceptable);
  5. Patients are eligible regardless of whether mesh is used in the reconstruction surgery;
  6. Patients with severe breast ptosis are eligible;
  7. During the study observation period, lipofilling is permitted on the affected breast and symmetrization procedures on the contralateral breast in both cohorts;
  8. performance status 0-1;
  9. Patients receiving neoadjuvant chemotherapy (NACT) are eligible;
  10. Bilateral breast reconstruction is permitted;
  11. No smoking history OR smoking cessation ≥4 weeks prior to enrollment;
  12. Investigator-confirmed protocol compliance capability;
  13. Concurrent participation in other interventional/non-interventional trials is allowed if deemed non-interfering by the investigator;
  14. Voluntarily participate and sign the form after comprehensive understanding.

Exclusion criteria

Exclusion Criteria:

  1. Stage IV () breast cancer;
  2. No prior radiotherapy post-mastectomy;
  3. History of ipsilateral chest wall/axillary radiation therapy;
  4. Immunodeficiency, poorly controlled diabetes ( >7%), or active tobacco use;
  5. Inflammatory breast cancer (cT4d);
  6. Autologous-based breast reconstruction or delayed reconstruction;
  7. Severe cardiopulmonary/hepatic/renal comorbidities contraindicating surgery/radiotherapy ( ≥III);
  8. Psychiatric disorders precluding independent BREAST-Q completion;
  9. Pregnancy or lactation;
  10. Documented history of protocol non-adherence;
  11. Life-limiting comorbidities interfering with treatment OR investigator-determined ineligibility.
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

ASA physical status

The anaesthetists’ scale of health before surgery: I is healthy, II has a mild illness that is under control, III a severe one, IV a severe illness that is a constant threat to life. V and VI are used for the critically ill and for organ donors.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
104 participants (estimated)
Patient registry
No

Groups and cohorts

  • Immediate One-Stage Prepectoral Prosthetic Breast Reconstruction Cohort

    Patients undergoing nipple-sparing mastectomy (NSM) or skin-sparing mastectomy (SSM) with immediate prepectoral prosthetic breast reconstruction are eligible for inclusion, regardless of mesh use (with or without mesh). Approaches including open, endoscopic, or robotic techniques are acceptable, provided that adjuvant radiotherapy is administered after permanent implant placement.

    Procedure: Breast Reconstruction Surgery

  • Delayed-Immediate Two-Stage Expander/Implant Breast Reconstruction Cohort

    Patients undergoing nipple-sparing mastectomy (NSM) or skin-sparing mastectomy (SSM) with two-stage expander/implant breast reconstruction are eligible, provided that: Expander placement may be either prepectoral or subpectoral, Mesh use is optional (with or without acellular dermal matrix), Radiotherapy is administered with the expander in situ, Permanent implant exchange is performed ≥6 months after completing radiotherapy, The implant exchange procedure permits any approach (open, endoscopic, or robotic) and any plane/mesh configuration (prepectoral/subpectoral, with/without mesh).

    Procedure: Breast Reconstruction Surgery

Interventions

  • ProcedureBreast Reconstruction Surgery

    Breast Reconstruction Surgery (either immediate one-stage prepectoral implant reconstruction or two-stage expander/implant reconstruction) with postoperative adjuvant radiotherapy

    Also known as: radiation

06

What researchers measure

Primary outcomes

  1. BREAST-Q (Breast Reconstruction Module) Scores

    This trial collects patient-reported outcomes through four domains of the BREAST-Q Breast Reconstruction Module: Satisfaction with Breasts, Psychosocial Well-being, Physical Well-being, Sexual Well-being. Scores are assessed preoperatively and at 12 months postoperatively. The BREAST-Q score at 12 months post-surgery serves as the primary endpoint.

    Time frame: Preoperatively and at 1 Year Postoperatively

Secondary outcomes

  1. Breast Reconstruction Failure Rate

    Breast Reconstruction Failure Rate: Defined as the proportion of patients requiring implant removal due to complications among all patients undergoing breast reconstruction. Implant Removal Due to Complications: Refers to explantation occurring within 12 months postoperatively attributed to any of the following surgery-related complications: Hematoma, Seroma, Flap necrosis, Nipple-areolar complex (NAC) necrosis, Surgical site infection, Wound dehiscence, Implant exposure, Baker grade III/IV capsular contracture, Implant malposition/displacement. Exclusion Criterion: Implant removals requested by patients without objective surgery-related complications (i.e., subjectively motivated explantations) must be documented separately and excluded from failure rate calculations.

    Time frame: 1 Year Postoperatively

  2. Complication Profile:

    Includes but not limited to: Hematoma, Poor Wound Healing, Flap Necrosis, Surgical Site Infection, Wound Dehiscence, Fat Grafting-Associated Complications. All complications must be graded according to the Clavien-Dindo Classification System, then systematically assessed and documented.

    Time frame: 1 Year Postoperatively

  3. Physician-Assessed Aesthetic Outcome

    Evaluated by surgeons independent of the operating team using the Harris Scale to grade the aesthetic outcome of the reconstructed breast based on standardized patient photographs.

    Time frame: 1 Year Postoperatively

  4. Capsular Contracture Assessment

    Evaluated using the Baker Classification System (Spear \& Baker, 1995).

    Time frame: 1 Year Postoperatively

  5. Nipple and Skin Sensation Assessment

    Tactile sensation is evaluated using the Semmes-Weinstein Monofilament Examination (SWME).

    Time frame: 1 Year Postoperatively

  6. Oncological Safety Endpoints: Disease-Free Survival (DFS) and Overall Survival (OS).

    DFS: Time interval from the date of surgery to the occurrence of any recurrence (local/regional/distant metastasis), new primary breast cancer, or death from any cause, whichever occurs first. Patients without events are censored at the last documented disease-free follow-up. OS: Time interval from the date of surgery to death from any cause. Living patients are censored at the last confirmed survival follow-up.

    Time frame: 5 Year Postoperatively

07

Study locations

1 of 1 sites recruiting
08

References and documents

Publications

  • Kraenzlin F, Chopra K, Kokosis G, Venturi ML, Mesbahi A, Nahabedian MY. Revision Breast Reconstruction with Prepectoral Pocket Conversion of Submuscular Breast Implants. Plast Reconstr Surg. 2021 May 1;147(5):743e-748e. doi: 10.1097/PRS.0000000000007885. PubMed 33890886 ↗
  • Chatterjee A, Nahabedian MY, Gabriel A, Macarios D, Parekh M, Wang F, Griffin L, Sigalove S. Early assessment of post-surgical outcomes with pre-pectoral breast reconstruction: A literature review and meta-analysis. J Surg Oncol. 2018 May;117(6):1119-1130. doi: 10.1002/jso.24938. Epub 2018 Jan 18. PubMed 29346711 ↗
  • Li Y, Xu G, Yu N, Huang J, Long X. Prepectoral Versus Subpectoral Implant-Based Breast Reconstruction: A Meta-analysis. Ann Plast Surg. 2020 Oct;85(4):437-447. doi: 10.1097/SAP.0000000000002190. PubMed 31913902 ↗
  • Sigalove S. Prepectoral breast reconstruction and radiotherapy-a closer look. Gland Surg. 2019 Feb;8(1):67-74. doi: 10.21037/gs.2019.01.01. PubMed 30842930 ↗
  • Gabriel A, Maxwell GP. Prepectoral Breast Reconstruction in Challenging Patients. Plast Reconstr Surg. 2017 Dec;140(6S Prepectoral Breast Reconstruction):14S-21S. doi: 10.1097/PRS.0000000000004046. PubMed 29166343 ↗
  • Chopra S, Al-Ishaq Z, Vidya R. The Journey of Prepectoral Breast Reconstruction through Time. World J Plast Surg. 2021 May;10(2):3-13. doi: 10.29252/wjps.10.2.3. PubMed 34307092 ↗
  • Clemens MW, Kronowitz SJ. Acellular dermal matrix in irradiated tissue expander/implant-based breast reconstruction: evidence-based review. Plast Reconstr Surg. 2012 Nov;130(5 Suppl 2):27S-34S. doi: 10.1097/PRS.0b013e318265f690. PubMed 23096982 ↗
  • Kronowitz SJ, Hunt KK, Kuerer HM, Babiera G, McNeese MD, Buchholz TA, Strom EA, Robb GL. Delayed-immediate breast reconstruction. Plast Reconstr Surg. 2004 May;113(6):1617-28. doi: 10.1097/01.prs.0000117192.54945.88. PubMed 15114121 ↗
  • Sbitany H, Gomez-Sanchez C, Piper M, Lentz R. Prepectoral Breast Reconstruction in the Setting of Postmastectomy Radiation Therapy: An Assessment of Clinical Outcomes and Benefits. Plast Reconstr Surg. 2019 Jan;143(1):10-20. doi: 10.1097/PRS.0000000000005140. PubMed 30589770 ↗
  • Garza RM, Paik KJ, Chung MT, Duscher D, Gurtner GC, Longaker MT, Wan DC. Studies in fat grafting: Part III. Fat grafting irradiated tissue--improved skin quality and decreased fat graft retention. Plast Reconstr Surg. 2014 Aug;134(2):249-257. doi: 10.1097/PRS.0000000000000326. PubMed 25068325 ↗
  • Cano SJ, Klassen AF, Scott AM, Cordeiro PG, Pusic AL. The BREAST-Q: further validation in independent clinical samples. Plast Reconstr Surg. 2012 Feb;129(2):293-302. doi: 10.1097/PRS.0b013e31823aec6b. PubMed 22286412 ↗
  • Voineskos SH, Nelson JA, Klassen AF, Pusic AL. Measuring Patient-Reported Outcomes: Key Metrics in Reconstructive Surgery. Annu Rev Med. 2018 Jan 29;69:467-479. doi: 10.1146/annurev-med-060116-022831. PubMed 29414263 ↗
09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started May 2025 (actual). Primary completion is estimated for Mar 2027, 22 months after the start.

Of 1,193 non-industry observational studies under Breast Neoplasms, half reached primary completion within 58 months of starting (the median), counting those still running; a quarter within 25 and three quarters within 139. This study's planned 22 months is below that.

Counting every sponsor, half of 1,382 studies reached it within 55 months; a quarter within 25 and three quarters within 126.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 17, 2025
First posted
Jun 25, 2025
StartActual
May 20, 2025
Primary completionEst.
Mar 30, 2027
CompletionEst.
Mar 30, 2028
Last update
Jun 25, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 25, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07037576
Responsible party
Sponsor
First posted
Jun 25, 2025
Start date
May 20, 2025
Primary completion
Mar 30, 2027 (estimated)
Completion
Mar 30, 2028 (estimated)
Last update
Jun 25, 2025

Study contacts

xiuchun Chen
Contact
cxc701024@163.com
18603719919
minhao Lv
Contact
lvminhao2004628@163.com
13838392355
xiuchun chen
study director · Henan Cancer Hospital

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion